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Significance of this study
What is already known on this topic?
 ► The use of palliative indwelling drains for 
ascites complicating malignancy or even 
chronic heart failure is established. Large 
published series of the use of such drains 
in the setting of ascites complicating liver 
cirrhosis to date are largely lacking.
What this study adds?
 ► This study adds data regarding the 
applicability, acceptable safety and clinical 
outcomes of the use of palliative tunnelled 
ascitic drains, in those patients deemed by 
a multi- disciplinary team decision not to 
be candidates for transplantation or other 
treatments for ascites.
How might it impact on clinical 
practice?
 ► Use of tunnelled indwelling drains in the 
appropriate selected patients with liver 
cirrhosis and refractory ascites can be 
considered in a palliative setting. Careful 
patient selection remains key, along with 
centre- experience in placement of drains. 
Patients however if appropriate should 
be considered for TIPSS or transplant 
assessment when ascites complicates 
cirrhosis prior to indwelling tunnelled 
drains being inserted.
AbstrAct
Objective Refractory ascites is an established 
indication for liver transplantation. While 
transplantation is regarded as the definitive 
therapy for this condition, many patients 
are unsuitable due to comorbidity or frailty. 
Alternatives such as transjugular intrahepatic 
portosystemic shunt (TIPSS) and large- volume 
paracentesis can lead to complications, 
including encephalopathy, circulatory and 
renal dysfunction, and protein–calorie 
deficiency that may accelerate sarcopenia. 
Cost and complication rates limit therapies 
such as alfapump. While there are data to 
support the use of indwelling catheters in 
the management of patients with malignant 
ascites, there is limited evidence to support 
their routine use in the context of end- stage 
liver cirrhosis. Here we describe our centres’ 
experience using indwelling tunnelled ascitic 
drains over a 6- year period.
Methods A retrospective review of data (January 
2012–May 2018) was undertaken for all 
patients with refractory ascites who underwent 
a tunnelled ascitic drain. Demographics, disease 
aetiology, procedure data and follow- up 
data were obtained through interrogation of 
electronic records and reports.
Results Twenty- five drains were placed. All 
procedures were technically successful with 
no immediate complications. Six patients were 
readmitted following their index admission  
with abdominal pain and suspected infected 
ascites (although only two had a positive 
ascitic fluid culture). There were three cases of 
abdominal wall cellulitis and three of leakage 
around the tunnel site; all managed  
conservatively.
Conclusion Indwelling drains appear an 
effective strategy for palliative management of 
select patients with liver cirrhosis complicated 
by refractory ascites who are not amenable 
to undergo TIPSS or transplantation. While 
complications can occur, these are most usually 
minor and can be managed on an outpatient 
basis.
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summAry
Tunnelled peritoneal drains are widely used in patients 
with malignant ascites, but there are limited data 
regarding their safety and effectiveness in patients with 
cirrhosis and refractory ascites. The data presented 
in our case series of 25 patients with end- stage liver 
disease not suitable for transjugular intrahepatic porto-
systemic shunt or transplantation demonstrate that 
these devices can be safely used in this population. 
However, further randomised studies are needed.
IntroductIon
The development of ascites is an established compli-
cation of portal hypertension occurring in up to 60% 
of patients within 10 years of being diagnosed with 
cirrhosis.1 The presence of ascites, which is refrac-
tory to diuretics, acts as a marker of poor prognosis 
with 50% of patients dying within 6 months of onset.2 
The presence of ascites can also significantly reduce 
a patient’s quality of life and worsen sarcopenia. 
Liver transplantation (LT) should be considered in 
all patients as a definitive and curative intervention, 
although not all patients will be suitable. Radiological 
techniques such as insertion of a transjugular intrahe-
patic portosystemic shunt (TIPSS) may be considered 
either as a definitive (although non- curative) treatment 
or, in select patients, as a bridge to an LT when opti-
misation is needed before a patient can be listed. For 
patients where LT and TIPSS are inappropriate and the 
burden of intermittent arge volume paracentesis (LVP) 
is high, there are few alternative therapies available. 
These patients often require multiple admissions to the 
hospital, which can have both a cost and bed- resource 
implications for hospitals3 and can be associated with 
a significant impact on the patients with constraints on 
the timing of drainage and the associated burden of 
regular hospital attendances. The use of tunnelled peri-
toneal drains may represent a more durable, sustain-
able and compassionate solution for select patients 
entering the palliative phase of their disease.
When undertaken under image guidance, procedural 
complications related to the insertion of tunnelled 
peritoneal drains such as visceral injury and haemo-
peritoneum are almost non- existent as evidenced by 
the outcomes from studies of the use of these devices in 
patients with malignant ascites. Two recently published 
studies looking at patients with malignant ascites 
reported 100% technical success and no immediate 
procedural complications.4 5 However, there remains a 
paucity of literature describing the safety data related 
to the use of long- term catheters in patients with 
cirrhosis, although the data available suggest that these 
are safe within this population.6 7
To date, no prospective studies or trials in this area 
have been published, although interest in this area 
is increasing; in Denmark, a randomised controlled 
trial (RCT) study of LVP versus PleurX is currently 
recruiting patients but is not due to be completed until 
2022,8 while in the UK, preliminary data from a feasi-
bility RCT comparing LVP and drain insertion support 
the safety and efficacy of these devices.9
In this paper, we describe our experience using 
tunnelled peritoneal drains (PleurX) in patients with 
end- stage cirrhosis and refractory ascites who were 
deemed unsuitable for TIPSS or LT.
mAterIAls And methods
study population
A retrospective review of the hospital’s radiology 
department patient database was performed, identi-
fying all patients who had a tunnelled peritoneal drain 
for any indication between January 2012 and April 
2018. From this cohort, all those who had a tunnelled 
drain for ascites on a background of cirrhosis were 
identified. Patient demographic and preprocedural data 
were collected from the electronic records, including 
patient age, sex, the aetiology of liver disease, number 
of previous LVP, disease severity scores (Model for 
End- Stage Liver Disease (MELD) and Child- Pugh 
score). Procedural data were obtained from the local 
patient information system and radiology electronic 
system.
All patients considered for tunnelled drain inser-
tion were discussed via an MDT approach involving 
a hepatologist, palliative care consultant and specialist 
liver cirrhosis nurse, where their suitability for 
tunnelled drain insertion was determined. Contrain-
dications to the insertion of tunnelled drain included 
the presence of loculated ascites and active abdominal 
wall infection. Previous spontaneous bacterial perito-
nitis (SBP) was not an absolute contraindication but 
was considered when deciding on the appropriateness 
of tunnelled drain insertion and the need for post-
procedure antibiotic use with regard to coagulopathy. 
While the insertion of a temporary ascitic drain can be 
undertaken in patients with cirrhosis and an interna-
tional normalised ratio (INR) of >1.5, the insertion 
of a permanent ascitic drain requires tunnelling of the 
drain in the abdominal wall, which is associated with a 
higher risk of bleeding. As such, radiology department 
guidelines within our institution state the need for an 
INR of 1.5 or less. While for patients with end- stage 
liver disease this may not be a significant coagulopathy, 
for the purpose of undertaking this specific interven-
tional radiology procedure, it is deemed to be signifi-
cant and required correction before the procedure can 
be undertaken.
outcomes
The primary outcome measured was event- free survival 
of the tunnelled peritoneal drain. This was defined as 
the number of days since placement of drain without 
intervention or removal. Event endpoints were 
patient death or drain removal/replacement for any 
reason. Secondary outcomes noted were any drain- 
related complication expressed according to Common 
Corrigan M, et al. Frontline Gastroenterology 2021;12:108–112. doi:10.1136/flgastro-2019-101332110
Liver
Figure 1 Number of PleurX drains inserted per calendar from the 
beginning of the use of the devices in 2012 until the end of the data 
collection period.
Table 1 Patient characteristics
Patient characteristics (n=25)
Age, median (range) 69 (48–83)
M:F 17:8
Concurrent HCC 9 (36%)
Aetiology of cirrhosis*
  ARLD 12
NASH 10
  Cryptogenic 2
  HBV/HCV 3
  Other 3
Classification of liver function
  MELD score, median (range) 15 (7–25)
  Child- Pugh classification B, 22 (88%); C, 3 (12%)
*n>25 as some patients had more than one aetiology to their liver 
disease.
ARLD, Alcohol related liver disease; F, female; HBV, hepatitis B virus; 
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; M, male; MELD, 
Model for End- Stage Liver Disease; NASH, Non- alcoholic steatohepatitis.
Terminology Criteria for Adverse Events (CTCAE)10 
and readmission rates, defined as the number of 
hospital admissions for complaints related to tunnelled 
peritoneal drain/ascites. As drains were inserted for 
palliative indications and managed within the commu-
nity, no follow- up data on the United Kingdom Model 
for End stage liver disease (UKELD)/MELD scores or 
renal function were collected.
statistical analysis
Data were collected and collated using Microsoft Excel 
2010. Mean (±SD) and median (range) were calcu-
lated for numerical data, and frequencies were calcu-
lated for categorical data. Kaplan- Meir survival curves 
were calculated for event- free survival following ascitic 
drains.
drain placement procedure
The procedure of placing the tunnelled peritoneal 
drain was as described further and as per manufacturer 
recommendations (PleurX, BD, USA). The use of the 
PleurX system in patients with cirrhosis and refrac-
tory ascites is considered an off- label indication, and 
this was discussed with each patient prior to insertion. 
The abdomen was scanned with ultrasound to iden-
tify a sufficiently large pocket of ascites. The identi-
fied area was cleaned, and a sterile field was estab-
lished. Local anaesthetic (lidocaine 1%) was injected 
subcutaneously at the point of intended puncture and 
then along the proposed tunnel (approximately 10 cm 
long). The tunnelled portion of the drain was directed 
centrally towards the umbilicus, a position practical 
for patient comfort and drain care. An Angiocath (BD, 
USA) coaxial needle was then used to puncture into 
the peritoneal cavity under ultrasound. The sheath 
was then advanced, and a standard wire (0.035- inch 
J- tip guidewire) was placed through the sheath, in the 
peritoneal cavity. A small incision was made in the 
skin at the puncture point and a second incision 5 cm 
away, towards the umbilicus. The ‘peritoneal’ end of 
the catheter was then attached and tunnelled subcuta-
neously between the two incisions, towards the wire, 
until the Dacron cuff was palpable in the tunnel. Dila-
tors were used over the wire before introduction of the 
peel- away sheath. The peel- away sheath was advanced 
and the catheter fed through, before removing the 
peel- away sheath. The incisions were then sutured, 
and a dressing was applied to fix the drain in place. 
One litre of ascites was drained in the procedure room, 
and the patient was then transferred back to the ward 
or the ambulatory care unit.
Standard postprocedure care involved 2 hours of bed 
rest and half hourly observations (including heart rate, 
blood pressure and temperature). Patients were not 
routinely placed on prophylactic antibiotics following 
the procedure. However, those on SBP prophylaxis 
continued this postprocedure. Where patients had 
large- volume ascites at the time of drain insertion, 
this was drained via the PleurX prior to discharge; if 
a total of >5 L was removed, then 100 mL of 20% 
human albumin solution was given for every 2–3 L 
drained. Following this, albumin was not routinely 
given for ongoing small- volume drainage. Further care 
and patient training were arranged in the community 
in conjunction with local district nurses. The amount 
drained per session and the frequency of drainage 
were directed initially by the discharging medical team 
and going forward, guided by patients’ symptoms and 
tolerance. Clinical follow- up of patients once drainage 
was established was at the discretion of their hepatolo-
gist. The end of follow- up was defined as the last docu-
mented clinical contact or death.
results
Twenty- five tunnelled peritoneal drains were placed in 
25 patients during the study period with the use of the 
drains becoming more frequent over time (figure 1). 
Patient demographics are summarised in table 1. The 
most common aetiology for cirrhosis was alcohol- 
related liver disease (n=12) followed by non- alcoholic 
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Table 2 Adverse events




Leakage 3 (12) Suture
Cellulitis 3 (12) Oral antibiotics





Drain malfunction 1 (4) Blocked, removed
Positive ascitic fluid 
culture
2 (8) Antibiotics
CTCAE, Common Terminology Criteria for Adverse Events.
steatohepatitis (n=10), viral hepatitis (n=3), crypto-
genic cirrhosis (n=2), primary sclerosing cholangitis 
(n=1), polycystic liver and kidney disease (n=1), and 
amyloid (n=1). In those patients with concurrent 
hepatocellular carcinoma (n=9, 36%), all diseases 
were confined to the liver with no extrahepatic or 
peritoneal disease, and the median MELD score 
was 15 (range 7–23), indicating the severity of their 
underlying liver dysfunction. Therefore, the presumed 
mechanism of action for the ascites was liver synthetic 
failure with an overall MELD score of 15 (range 7–25) 
for all patients.
All patients had undergone day case LVP in the 12 
months prior to the procedure, with a median number 
of three drainage episodes required per patient (range 
1–50). Seven patients (28%) had a previous episode of 
SBP. While LT had been considered in all 25 patients, 
advancing age and poor physiological reserve were 
deemed a contraindication in 4 cases (16%), major 
comorbidity in 13 cases (52%), active or past malig-
nancy in 4 cases (16%) and ongoing alcohol use/concern 
regarding recidivism in 3 cases (12%). Twenty- one of 
the 25 patients (84%) were formally referred to palli-
ative care services (18 via hospital- based services and 
3 to local community services). Nine patients (36%) 
were formally assessed for TIPSS but were deemed to 
be inappropriate: four had previous or current hepatic 
encephalopathy (HE); four had a significant cardiopul-
monary comorbidity; and one patient had a portal vein 
thrombosis, meaning that TIPSS was technically not 
feasible.
Procedure outcomes
Drain placement was technically successful in all 25 
cases. There were no immediate complications after 
drain placement and no complications that developed 
during the index admission of the patient. Fourteen 
drains (56%) were carried out as day case procedures 
through the hospital ambulatory care unit with the 
remainder carried out during an inpatient stay. The 
median length of stay post drain was 3 days (range 
0–33). Delayed complications are summarised in 
table 2 and are graded according to the CTCAE. The 
median time to the last follow- up or death was 90 
days (range 8–675). Ten of the patients (40%) had no 
recorded drain- related complications or readmissions. 
Of the remaining 15 patients, 6 (40%) were read-
mitted following their index admission. Two patients 
had a positive ascitic fluid culture (one grew acin-
obacter and the other a vancomycin- sensitive ente-
rococcus) and were treated with appropriate antibi-
otics. Two patients had negative ascitic fluid cultures 
(one had an ascitic white cell count of >250) but 
were treated with antibiotics. The other two patients 
(one of which was admitted to an external hospital) 
were treated for presumed SBP without ascitic fluid 
sampling. Symptoms settled in all patients and none 
required drain removal. None of these patients devel-
oped event recurrence. Minor complications (not 
requiring readmission) included three cases of superfi-
cial cellulitis, managed with oral antibiotics and three 
cases of leakage around the tunnel site, which were 
treated definitively with a purse- string suture again. 
One drain was removed as it became blocked and a 
muliti- disciplnary meeting (MDT) decision was made 
not to replace it. The Kaplan- Meier curve (figure 2) 
demonstrates the survival of patients with tunnelled 
peritoneal drains. More than 50% of patients survived 
>200 days with drains in situ. This is in keeping with 
published mortality rates for patients with refractory 
ascites.
dIscussIon
This study, to our knowledge, represents one of the 
largest cohort of patients with cirrhosis undergoing 
insertion of a tunnelled peritoneal drain for the 
management of refractory ascites. While insertion 
of this device is regarded as standard practice in the 
palliation of patients with recurrent malignant ascites, 
its use in patients with underlying cirrhosis is not yet 
widespread and its utility, safety and cost effectiveness 
in this context remain to be established. Currently, 
LVP is the standard of care for patients with refractory 
ascites not suitable for TIPSS or LT, and is known to 
be a safe procedure with a relatively low complication 
rate.2 This approach, however, can be burdensome 
for patients entering a palliative phase of their illness. 
The convenience, durability and ease of use of these 
indwelling drains facilitate community management 
and can prevent frequent hospital admissions for para-
centesis. In terms of cost, a review by National Insti-
tute for Health and Clinical Evidence suggested a cost 
saving of £1051 per patient when compared with inpa-
tient LVP with malignant ascites.11 However, savings 
are not seen in patients where LVP can be offered 
on an outpatient basis. Further data are needed to 
compare ambulatory LVP and peritoneal drain inser-
tion in patients with cirrhosis.
Our experience confirms that the indwelling cath-
eters can be used over long periods (with 50% 
surviving over 200 days) with an acceptable rate of 
complications which are similar to those reported in 
other studies. Where complications did occur in our 
series, all patients who experienced a drain leak were 
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Figure 2 Kaplan- Meier survival curve demonstrating intervention- 
free drain survival.
managed as outpatients with insertion of a purse- 
string suture, and those who developed superficial 
cellulitis were managed with oral antibiotics at home. 
The most significant complication was that of culture- 
proven bacterial peritonitis which was diagnosed in 
two patients (8%). This complication has also been 
reported in other studies of tunnelled ascitic drains for 
both non- malignant and malignant ascites and in our 
series was successfully managed with intravenous anti-
biotics with the drain left in situ. Neither of the two 
patients in our cohort was systemically unwell or had 
signs of sepsis.
While the outcomes of this study are positive, it is 
not without its limitations. Compared with the data 
in malignant ascites, it is a small case series with data 
having been collected retrospectively, which prevented 
any detailed comparative subanalyses of data.
In addition, data on quality of life scores were not 
collected within our case series. Given the nature 
of the patient cohort, it would be beneficial for any 
prospective studies to incorporate quality of life data 
collection predrain and postdrain insertion. The role 
of prophylactic antibiotics also requires further study, 
especially in view of risks of antibiotic resistance and 
Clostridium difficile.
conclusIon
Tunnelled peritoneal drains appear an effective strategy 
for community management and palliation of refrac-
tory ascites in patients with end- stage cirrhosis. The 
regular use of indwelling peritoneal catheters has the 
potential to prevent repeated hospital admission, save 
on inpatient costs and allow patients to be managed in 
their own homes. The use of the catheters is associated 
with an acceptable rate of manageable complications 
in patients entering a palliative phase of their illness. 
Appropriate patient selection, multidisciplinary discus-
sion and shared protocols for the use of the drains are 
vital.
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